Navigation Links
Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
Date:6/7/2012

HOBOKEN, N.J., June 7, 2012 /PRNewswire/ -- The body's first line of defense against coronary artery disease, the most common type of heart disease, are endothelial cells. These cells serve as the "traffic cop" for blood flow, directing blood to the appropriate area of the body such as the heart, brain, muscles or digestive system to support the body's actions. A study published in the January 2012 issue of European Heart Journal found that natural supplement Pycnogenol® (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree and natural solution for heart health, improves endothelial function in patients with stable coronary artery disease. 

"When coronary arteries are narrowed or blocked by plaque build-up, oxygen-rich blood cannot reach the heart muscle, often leading to a heart attack," says Dr. Frank Enseleit, the lead study researcher. "The results of this study show for the first time that Pycnogenol® significantly improves endothelial function and blood flow in patients with coronary heart disease."

The randomized, double-blind, placebo-controlled, crossover study was carried out at the Clinic for Cardiology at the University Hospital Zurich in Switzerland. The study investigated 23 patients with stable coronary artery disease, as documented by coronary angiography, nuclear imaging or positive stress test.

Patients were assigned to two groups. Patients in Group One received Pycnogenol® (200 mg/d) for eight weeks, then took placebo for another eight weeks. Group Two received the opposite sequence of placebo first, followed by eight weeks with Pycnogenol®. Before and after the eight weeks of treatment, blood samples were taken and the flow-mediated dilatation of the brachial arteries in the upper arm was established.


After eight weeks of treatment with Pycnogenol® the study found:

  • Pycnogenol® increased artery dilation by 32 percent, a significant change, while it remained unchanged in the placebo group
  • Pycnogenol® significantly reduced plasma-8-isoprostaries, an index of oxidative stress
  • Pycnogenol® demonstrated significant effects on a critical measure of endothelial function, reducing plasma levels of endothelin-1

"The balance between endothelial function and dysfunction plays an important role in the transition from a stable to an unstable disease state. As such, the evaluation of endothelial function has emerged as an important end point in cardiovascular research," says Dr. Frank Enseleit. "After Pycnogenol® usage, we were able to identify a significant improvement of endothelial function in individuals who depend on medications as a result of their heart disease. Pycnogenol® appears to help restore a body's own functions in flow-mediated arterial dilatation."

This groundbreaking study further strengthens Pycnogenol®'s already large arsenal of cardiovascular health benefits. Past clinical trials have shown beneficial effects of Pycnogenol® on chronic inflammation as well as cardiovascular risk factors including hypertension, cholesterol and platelet function. This new study also provides further evidence on the safety of Pycnogenol® for patients taking cardiovascular medicines.

About Pycnogenol®

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits.  The extract has been widely studied for the past 40 years and has more than 280 published studies and review articles ensuring safety and efficacy as an ingredient.  Today, Pycnogenol® is available in more than 700 dietary supplements, multi-vitamins and health products worldwide.  For more information, visit www.pycnogenol.com.

About Horphag Research (USA) Inc.

Horphag Research (USA) Inc., based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol® is a registered trademark of Horphag Research Ltd., Guernsey, and is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award.  Horphag Research (USA) has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.  For more information about Pycnogenol® visit www.pycnogenol.com.

Related Link:
Pycnogenol Facebook page


'/>"/>
SOURCE Horphag Research (USA) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
3. Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed®
4. Accident Fund Holdings Aims to Improve Control of Drug Utilization and Quality of Care with Change in Pharmacy Benefit Manager
5. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
6. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
7. IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve womens health and prenatal care
8. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
9. Stereotaxis Reports Improved First Quarter 2012 Financial Results
10. National Stakeholders Meet To Consider Improvements In Antimicrobial Use In Food Animal Production
11. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):